Please use this identifier to cite or link to this item:
https://scholars.lib.ntu.edu.tw/handle/123456789/494556
Title:
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial